MedTrace Logo

A Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature

NCT02505048 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 41

Last updated 2021-06-08

No results posted yet for this study

Summary

The purpose of this study is to assess the efficacy of a PARP inhibitor, rucaparib, in progressing breast cancer patients and who are carrying a BCRAness profile defined by genomic signature or BRCA 1 or 2 somatic mutation, without known BRCA 1 or 2 germline mutation.

Conditions

Interventions

DRUG

rucaparib

600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.

Sponsors & Collaborators

  • Clovis Oncology, Inc.

    collaborator INDUSTRY

  • Fondation ARC

    collaborator OTHER

  • UNICANCER

    lead OTHER

Principal Investigators

  • Fabrice André, MD PhD · Gustave Roussy Villejuif

  • Anne Patsouris, MD · Institut de Cancerologie de l'Ouest Paul Papin

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2019-02-28
Completion
2019-12-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02505048 on ClinicalTrials.gov